Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Carolyn A. Taylor PhD

Carolyn A. Taylor PhD

Adjunct Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Bone Marrow Transplant

Member of the Cancer Center


Research Experience

  • Biological Phenomena, Cell Phenomena, and Immunity
  • Biological Sciences Category
  • Cytotoxicity, Immunologic
  • Graft vs Host Reaction
  • Histocompatibility
  • Host vs Graft Reaction
  • Immunity
  • Immunity, Cellular
  • Transplantation Immunology
  • Methodologies and Techniques

  • Analytical, Diagnostic and Therapeutic Techniques and Equipment Category
  • Biological Therapy
  • Biomedical Research
  • Bone Marrow Transplantation
  • Cell Culture Techniques
  • Cord Blood Stem Cell Transplantation
  • Culture Techniques
  • Hematopoietic Stem Cell Transplantation
  • Human Experimentation
  • Immunization
  • Immunization, Passive
  • Immunologic Techniques
  • Immunologic Tests
  • Immunotherapy
  • Immunotherapy, Active
  • Investigative Techniques
  • Peripheral Blood Stem Cell Transplantation
  • Preservation, Biological
  • Therapeutic Human Experimentation
  • Therapeutics
  • Tissue Engineering
  • MCW Program / Core Facilities

  • Lymphocyte Propagation Laboratory (LPL)
      Dr. Taylor is the Director of the LPL. Cellular Therapy Products to be used for immunotherapy are processed within this laboratory.
  • Publications

  • Manufacture of Autologous CD34(+) Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases. (Keever-Taylor CA, Heimfeld S, Steinmiller KC, Nash RA, Sullivan KM, Czarniecki CW, Granderson TC, Goldstein JS, Griffith LM) Biol Blood Marrow Transplant 2017 Sep;23(9):1463-1472 PMID: 28602891 06/13/2017
  • Training practices of cell processing laboratory staff: analysis of a survey by the Alliance for Harmonization of Cellular Therapy Accreditation. (Keever-Taylor CA, Slaper-Cortenbach I, Celluzzi C, Loper K, Aljurf M, Schwartz J, Mcgrath E, Eldridge P, Alliance for Harmonisation of Cellular Therapy Accreditation) Cytotherapy 2015 Dec;17(12):1831-44 PMID: 26455277 10/13/2015
  • Hydroxyethyl starch as a substitute for dextran 40 for thawing peripheral blood progenitor cell products. (Zhu F, Heditke S, Kurtzberg J, Waters-Pick B, Hari P, Margolis DA, Keever-Taylor CA) Cytotherapy 2015 Dec;17(12):1813-9 PMID: 26454752 10/12/2015
  • Training practices of hematopoietic progenitor cell-apheresis and -cord blood collection staff: analysis of a survey by the Alliance for Harmonisation of Cellular Therapy Accreditation. (Celluzzi CM, Keever-Taylor C, Aljurf M, Koh MB, Rabe F, Rebulla P, Sacchi N, Sanders J, McGrath E, Loper K, Alliance for Harmonisation of Cellular Therapy Accreditation (AHCTA)) Transfusion 2014 Dec;54(12):3138-44 PMID: 24947542 06/21/2014
  • Essential requirements for setting up a stem cell processing laboratory. (Leemhuis T, Padley D, Keever-Taylor C, Niederwieser D, Teshima T, Lanza F, Chabannon C, Szabolcs P, Bazarbachi A, Koh MB, Graft Processing Subcommittee of the Worldwide Network for Blood and Bone Marrow Transplantation (WBMT)) Bone Marrow Transplant 2014 Aug;49(8):1098-105 PMID: 24933209 06/17/2014
  • Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome. (Törlén J, Ringdén O, Le Rademacher J, Batiwalla M, Chen J, Erkers T, Ho V, Kebriaei P, Keever-Taylor C, Kindwall-Keller T, Lazarus HM, Laughlin MJ, Lill M, O'Brien T, Perales MA, Rocha V, Savani BN, Szwajcer D, Valcarcel D, Eapen M) Biol Blood Marrow Transplant 2014 Sep;20(9):1418-25 PMID: 24892261 PMCID: PMC4127369 06/04/2014
  • Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. (Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus HM, Appelbaum FR, Keever-Taylor CA, Horowitz MM, Carter S, O'Reilly RJ, Soiffer RJ) J Clin Oncol 2012 Sep 10;30(26):3194-201 PMID: 22869882 PMCID: PMC3434978 08/08/2012
  • Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. (Keever-Taylor CA, Devine SM, Soiffer RJ, Mendizabal A, Carter S, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Goldstein SC, Stadtmauer EA, O'Reilly RJ) Biol Blood Marrow Transplant 2012 May;18(5):690-7 PMID: 21875505 PMCID: PMC3762249 08/31/2011
  • Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. (Devine SM, Carter S, Soiffer RJ, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Stadtmauer EA, Alyea EP 3rd, Keever-Taylor CA, O'Reilly RJ) Biol Blood Marrow Transplant 2011 Sep;17(9):1343-51 PMID: 21320619 PMCID: PMC3150599 02/16/2011
  • Generation of cytotoxic T-cell lines using overlapping pentadecapeptides derived from conserved regions of the adenovirus hexon protein. (Zhu F, Xu H, Tsao A, Margolis DA, Keever-Taylor CA) J Gen Virol 2010 Jun;91(Pt 6):1577-89 PMID: 20130135 02/05/2010
  • The effect of the composition of unrelated donor bone marrow and peripheral blood progenitor cell grafts on transplantation outcomes. (Collins NH, Gee AP, Durett AG, Kan F, Zhang MJ, Champlin RE, Confer D, Eapen M, Howard A, King R, Laughlin MJ, Plante RJ, Setterholm M, Spellman S, Keever-Taylor C, Wagner JE, Weisdorf DJ) Biol Blood Marrow Transplant 2010 Feb;16(2):253-62 PMID: 19822219 PMCID: PMC2952392 10/14/2009
  • Phenotyping studies of clonotypic B lymphocytes from patients with multiple myeloma by flow cytometry. (Conway EJ, Wen J, Feng Y, Mo A, Huang WT, Keever-Taylor CA, Hari P, Vesole DH, Chang CC) Arch Pathol Lab Med 2009 Oct;133(10):1594-9 PMID: 19792049 10/02/2009
  • Antiviral responses following L-leucyl-L-leucine methyl esther (LLME)-treated lymphocyte infusions: graft-versus-infection without graft-versus-host disease. (Filicko-O'Hara J, Grosso D, Flomenberg PR, Friedman TM, Brunner J, Drobyski W, Ferber A, Kakhniashvili I, Keever-Taylor C, Mookerjee B, Talano JA, Wagner JI, Korngold R, Flomenberg N) Biol Blood Marrow Transplant 2009 Dec;15(12):1609-19 PMID: 19744572 PMCID: PMC2783272 09/12/2009
  • Comparison of immune recovery in recipients of unmanipulated vs T-cell-depleted grafts from unrelated donors in a multicenter randomized phase II-III trial (T-cell depletion trial). (Keever-Taylor CA, Wagner JE, Kernan NA, Small TN, Carter SL, Thompson JS, Cloud GA, Lamb LS) Bone Marrow Transplant 2010 Mar;45(3):587-9 PMID: 19617904 PMCID: PMC5445657 07/21/2009
  • Multiple distinct clones may co-exist in different lineages in myelodysplastic syndromes. (Huang WT, Yang X, Zhou X, Monzon FA, Wen J, Hagenkord JM, Wu LY, Keever-Taylor C, Novoa-Takara L, Wong ST, Young K, Chang CC) Leuk Res 2009 Jun;33(6):847-53 PMID: 19084271 12/17/2008
  • Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma. (Drobyski WR, Hari P, Keever-Taylor C, Komorowski R, Grossman W) Bone Marrow Transplant 2009 Jan;43(2):169-77 PMID: 18762759 09/03/2008
  • Stimulation by means of dendritic cells followed by Epstein-Barr virus-transformed B cells as antigen-presenting cells is more efficient than dendritic cells alone in inducing Aspergillus f16-specific cytotoxic T cell responses. (Zhu F, Ramadan G, Davies B, Margolis DA, Keever-Taylor CA) Clin Exp Immunol 2008 Feb;151(2):284-96 PMID: 18005260 PMCID: PMC2276953 11/17/2007
  • Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. (Keever-Taylor CA, Browning MB, Johnson BD, Truitt RL, Bredeson CN, Behn B, Tsao A) Cytotherapy 2007;9(2):144-57 PMID: 17453966 04/25/2007
  • Alternative donor bone marrow transplant for children with Philadelphia chromosome ALL. (Talano JM, Casper JT, Camitta BM, Keever-Taylor CA, Murray KJ, Eapen M, Pierce KL, Margolis DA) Bone Marrow Transplant 2006 Jan;37(2):135-41 PMID: 16273115 11/08/2005
  • The implication of follicular lymphoma patients receiving allogeneic stem cell transplantation from donors carrying t(14;18)-positive cells. (McGregor DK, Keever-Taylor CA, Bredeson C, Schur B, Vesole DH, Logan B, Chang CC) Bone Marrow Transplant 2005 Jun;35(11):1049-54 PMID: 15821762 04/12/2005
  • Generation of cytotoxic T cell responses directed to human leucocyte antigen Class I restricted epitopes from the Aspergillus f16 allergen. (Ramadan G, Davies B, Kurup VP, Keever-Taylor CA) Clin Exp Immunol 2005 Apr;140(1):81-91 PMID: 15762878 PMCID: PMC1809331 03/15/2005
  • Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. (Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, O'Reilly RJ, Horowitz MM, Dupont B) Blood 2005 Jun 15;105(12):4878-84 PMID: 15731175 PMCID: PMC1894998 02/26/2005
  • Generation of Th1 T cell responses directed to a HLA Class II restricted epitope from the Aspergillus f16 allergen. (Ramadan G, Davies B, Kurup VP, Keever-Taylor CA) Clin Exp Immunol 2005 Feb;139(2):257-67 PMID: 15654824 PMCID: PMC1809287 01/19/2005
  • Generation of Aspergillus- and CMV- specific T-cell responses using autologous fast DC. (Ramadan G, Konings S, Kurup VP, Keever-Taylor CA) Cytotherapy 2004;6(3):223-34 PMID: 15203979 06/19/2004
  • Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. (Burt RK, Drobyski WR, Seregina T, Traynor A, Oyama Y, Keever-Taylor C, Stefka J, Kuzel TM, Brush M, Rodriquez J, Burns W, Tennant L, Link C) Exp Hematol 2003 Oct;31(10):903-10 PMID: 14550806 10/11/2003
  • Suppression of EBV release from irradiated B lymphoblastoid cell-lines: superior activity of ganciclovir compared with acyclovir. (Keever-Taylor CA, Behn B, Konings S, Orentas R, Davies B, Margolis D) Cytotherapy 2003;5(4):323-35 PMID: 12944239 08/29/2003
  • Tumor load in patients with follicular lymphoma post stem cell transplantation may correlate with clinical course. (Chang CC, Bredeson C, Juckett M, Logan B, Keever-Taylor CA) Bone Marrow Transplant 2003 Aug;32(3):287-91 PMID: 12858200 07/15/2003
  • IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. (Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Blazar BR, Burger SR, Panoskaltsis-Mortari A, Keever-Taylor CA, Zhang MJ, Miller JS) Bone Marrow Transplant 2003 Jul;32(2):177-86 PMID: 12838283 07/03/2003
  • Concurrent presence of both patient and donor t(14;18) in a follicular lymphoma patient after undergoing allogeneic BMT: implications for minimal residual disease detection post-transplant. (Rosenblum MD, Drobyski WR, Keever-Taylor C, Chang CC) Bone Marrow Transplant 2003 May;31(10):947-9 PMID: 12748676 05/16/2003
  • Process control: application to the cell processing laboratory. (Keever-Taylor CA) Cytotherapy 2000;2(1):63-73 PMID: 12042057 06/04/2002
  • Complement-mediated T-cell depletion of bone marrow: comparison of T10B9.1A-31 and Muromonab-Orthoclone OKT3. (Keever-Taylor CA, Craig A, Molter M, Fu P, Loebel A, Skonecki J, Zeng H, Giesen B) Cytotherapy 2001;3(6):467-81 PMID: 11953031 04/16/2002
  • Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. (Drobyski WR, Klein J, Flomenberg N, Pietryga D, Vesole DH, Margolis DA, Keever-Taylor CA) Blood 2002 Feb 01;99(3):806-14 PMID: 11806980 01/25/2002
  • Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. (Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, Rizzo D, Burns WH, Margolis DA, Vesole DH, Horowitz M, Zhang MJ, Juckett M, Drobyski WR) Biol Blood Marrow Transplant 2001;7(11):620-30 PMID: 11760150 01/05/2002
  • Factors affecting neutrophil and platelet reconstitution following T cell-depleted bone marrow transplantation: differential effects of growth factor type and role of CD34(+) cell dose. (Keever-Taylor CA, Klein JP, Eastwood D, Bredeson C, Margolis DA, Burns WH, Vesole DH) Bone Marrow Transplant 2001 Apr;27(8):791-800 PMID: 11477435 07/31/2001
  • Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells. (Keever-Taylor CA, Margolis D, Konings S, Sandford GR, Nicolette CA, Lawendowski C, Burns WH) Biol Blood Marrow Transplant 2001;7(5):247-56 PMID: 11400946 06/13/2001
  • Loss of renal function following bone marrow transplantation: an analysis of angiotensin converting enzyme D/I polymorphism and other clinical risk factors. (Juckett MB, Cohen EP, Keever-Taylor CA, Zheng Y, Lawton CA, Moulder JE, Klein J) Bone Marrow Transplant 2001 Feb;27(4):451-6 PMID: 11313676 04/21/2001
  • T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. (Drobyski WR, Hessner MJ, Klein JP, Kabler-Babbitt C, Vesole DH, Margolis DA, Keever-Taylor CA) Blood 1999 Jul 15;94(2):434-41 PMID: 10397710 07/09/1999
  • Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. (Burt RK, Traynor AE, Pope R, Schroeder J, Cohen B, Karlin KH, Lobeck L, Goolsby C, Rowlings P, Davis FA, Stefoski D, Terry C, Keever-Taylor C, Rosen S, Vesole D, Fishman M, Brush M, Mujias S, Villa M, Burns WH) Blood 1998 Nov 15;92(10):3505-14 PMID: 9808541 11/10/1998
  • Successful unrelated marrow transplantation for patients over the age of 40 with chronic myelogenous leukemia. (Drobyski WR, Pelz C, Kabler-Babbitt C, Hessner M, Baxter-Lowe LA, Keever-Taylor CA) Biol Blood Marrow Transplant 1998;4(1):3-12 PMID: 9701386 08/13/1998
  • T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up. (Juckett M, Rowlings P, Hessner M, Keever-Taylor C, Burns W, Camitta B, Casper J, Drobyski WR, Hanson G, Horowitz M, Lawton C, Margolis J, Peitryga D, Vesole D) Bone Marrow Transplant 1998 May;21(9):893-9 PMID: 9613781 06/05/1998
  • T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. (Burt RK, Traynor AE, Cohen B, Karlin KH, Davis FA, Stefoski D, Terry C, Lobeck L, Russell EJ, Goolsby C, Rosen S, Gordon LI, Keever-Taylor C, Brush M, Fishman M, Burns WH) Bone Marrow Transplant 1998 Mar;21(6):537-41 PMID: 9543056 05/30/1998
  • Automated nucleotide sequencing reveals substantial disparity between the HLA-A2 genes of bone marrow transplant recipients and donors. (Szmania S, Keever-Taylor C, Baxter-Lowe LA) Hum Immunol 1997 Aug-Sep;56(1-2):77-83 PMID: 9455496 08/01/1997
  • Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation. (Kawanishi Y, Passweg J, Drobyski WR, Rowlings P, Cook-Craig A, Casper J, Pietryga D, Garbrecht F, Camitta B, Horowitz M, Juckett M, Margolis D, Flomenberg N, Keever-Taylor CA) Bone Marrow Transplant 1997 Jun;19(11):1069-77 PMID: 9193748 06/01/1997
  • Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation. (Keever-Taylor CA, Passweg J, Kawanishi Y, Casper J, Flomenberg N, Baxter-Lowe LA) Bone Marrow Transplant 1997 May;19(10):1001-9 PMID: 9169644 05/01/1997
  • A new limiting dilution culture system for the detection of T cell subsets in T cell-depleted marrow grafts. (Kawanishi Y, Flomenberg N, Cook-Craig A, McFadden P, Garbrecht F, Keever-Taylor CA) J Hematother 1996 Oct;5(5):485-95 PMID: 8938520 10/01/1996
  • Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults. (Margolis D, Camitta B, Pietryga D, Keever-Taylor C, Baxter-Lowe LA, Pierce K, Kupst MJ, French J 3rd, Truitt R, Lawton C, Murray K, Garbrecht F, Flomenberg N, Casper J) Br J Haematol 1996 Jul;94(1):65-72 PMID: 8757510 07/01/1996
  • Hematologic and immunologic evaluation of recombinant human interleukin-6 in patients with advanced malignant disease: evidence for monocyte activation. (Keever-Taylor CA, Witt PL, Truitt RL, Ramanujam S, Borden EC, Ritch PS) J Immunother Emphasis Tumor Immunol 1996 May;19(3):231-43 PMID: 8811498 05/01/1996
  • Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. (Hessner MJ, Endean DJ, Casper JT, Horowitz MM, Keever-Taylor CA, Roth M, Flomenberg N, Drobyski WR) Blood 1995 Nov 15;86(10):3987-96 PMID: 7579370 11/15/1995
  • Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status. (Gorski J, Yassai M, Zhu X, Kissela B, Kissella B [corrected to Kissela B], Keever C, Flomenberg N) J Immunol 1994 May 15;152(10):5109-19 PMID: 8176227 05/15/1994
  • Effect of GVHD on the recovery of NK cell activity and LAK precursors following BMT. (Keever CA, Klein J, Leong N, Copelan EA, Avalos BR, Kapoor N, Cunningham I, Tutschka PJ) Bone Marrow Transplant 1993 Sep;12(3):289-95 PMID: 8241989 09/01/1993
  • B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny. (Small TN, Keever CA, Weiner-Fedus S, Heller G, O'Reilly RJ, Flomenberg N) Blood 1990 Oct 15;76(8):1647-56 PMID: 1698484 10/15/1990
  • Cytotoxic and proliferative T-cell clones with antidonor reactivity from a patient transplanted for severe combined immunodeficiency disease. (Keever CA, Flomenberg N, Gazzola MV, Pekle K, Yang SY, Small TN, Collins NH, O'Reilly RJ) Hum Immunol 1990 Sep;29(1):42-55 PMID: 2211189 09/01/1990
  • Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. (Hauch M, Gazzola MV, Small T, Bordignon C, Barnett L, Cunningham I, Castro-Malaspinia H, O'Reilly RJ, Keever CA) Blood 1990 Jun 01;75(11):2250-62 PMID: 2189508 06/01/1990
  • NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1. (Keever CA, Pekle K, Gazzola MV, Collins NH, Gillio A) Cell Immunol 1990 Mar;126(1):211-26 PMID: 1689220 03/01/1990
  • Both ongoing suppression and clonal elimination contribute to graft-host tolerance after transplantation of HLA mismatched T cell-depleted marrow for severe combined immunodeficiency. (Rosenkrantz K, Keever C, Bhimani K, Horvath A, Brochstein J, O'Reilly R, Dupont B, Flomenberg N) J Immunol 1990 Mar 01;144(5):1721-8 PMID: 2307837 03/01/1990
  • Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: II. In vitro analyses of host effector mechanisms. (Bordignon C, Keever CA, Small TN, Flomenberg N, Dupont B, O'Reilly RJ, Kernan NA) Blood 1989 Nov 01;74(6):2237-43 PMID: 2529927 11/01/1989
  • Loss of tolerance associated with disappearance of B cells in a patient sequentially transplanted with paternal and maternal bone marrow for the treatment of severe combined immunodeficiency disease. (Keever CA, Flomenberg N, Small T, Brochstein J, Collins N, Young-Yang S, Insel R, Dupont B, O'Reilly RJ) Hum Immunol 1989 Sep;26(1):27-38 PMID: 2528525 09/01/1989
  • Tolerance of engrafted donor T cells following bone marrow transplantation for severe combined immunodeficiency. (Keever CA, Flomenberg N, Brochstein J, Sullivan M, Collins NH, Burns J, Dupont B, O'Reilly RJ) Clin Immunol Immunopathol 1988 Sep;48(3):261-76 PMID: 3042210 09/01/1988
  • Interleukin 2-activated killer cells in patients following transplants of soybean lectin-separated and E rosette-depleted bone marrow. (Keever CA, Welte K, Small T, Levick J, Sullivan M, Hauch M, Evans RL, O'Reilly RJ) Blood 1987 Dec;70(6):1893-903 PMID: 3118990 12/01/1987
  • Interleukin-2 production and response to interleukin-2 by peripheral blood mononuclear cells from patients after bone marrow transplantation: II. Patients receiving soybean lectin-separated and T cell-depleted bone marrow. (Welte K, Keever CA, Levick J, Bonilla MA, Merluzzi VJ, Mertelsmann R, Evans R, O'Reilly RJ) Blood 1987 Nov;70(5):1595-603 PMID: 3311208 11/01/1987
  • Last update: 08/14/2017
    jenkins-FCD Prod-132 e0edc266de37dd13c3a3aec79eb87f3c7abc6fa4